Education
About Us
Working with TipRanks
Follow Us
NextCell Pharma AB (SE:NXTCL)
:NXTCL
RESEARCH TOOLSreports
NXTCL Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr0.69 - kr3.84
Previous CloseN/A
Volume77.06K
Average Volume (3M)385.23K
Market Cap
€103.72M
Enterprise Valuekr339.50M
Total Cash (Recent Filing)€26.34M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.46
Next Earnings
Jul 24, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding98,036,860
10 Day Avg. Volume355,765
30 Day Avg. Volume385,233
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)3.27
Price to Sales (P/S)0.00
P/FCF Ratio-5.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
NXTCL FAQ
What was NextCell Pharma AB’s price range in the past 12 months?
NextCell Pharma AB lowest stock price was kr0.69 and its highest was kr3.84 in the past 12 months.
What is NextCell Pharma AB’s market cap?
NextCell Pharma AB’s market cap is €103.72M.
When is NextCell Pharma AB’s upcoming earnings report date?
NextCell Pharma AB’s upcoming earnings report date is Jul 24, 2025 which is in 38 days.
How were NextCell Pharma AB’s earnings last quarter?
NextCell Pharma AB released its earnings results on Apr 25, 2025. The company reported -kr0.3 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.3.
Is NextCell Pharma AB overvalued?
According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued.
Does NextCell Pharma AB pay dividends?
NextCell Pharma AB does not currently pay dividends.
What is NextCell Pharma AB’s EPS estimate?
NextCell Pharma AB’s EPS estimate is -0.2.
How many shares outstanding does NextCell Pharma AB have?
NextCell Pharma AB has 98,036,860 shares outstanding.
What happened to NextCell Pharma AB’s price movement after its last earnings report?
NextCell Pharma AB reported an EPS of -kr0.3 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.269%.
Which hedge fund is a major shareholder of NextCell Pharma AB?
Currently, no hedge funds are holding shares in SE:NXTCL
Company Description
NextCell Pharma AB
NextCell Pharma AB (NXTCL) is a Swedish biopharmaceutical company focused on the development and commercialization of advanced therapies for immune-related diseases. The company specializes in stem cell-based treatments, with its flagship product, ProTrans, developed for the treatment of autoimmune conditions such as Type 1 Diabetes. NextCell Pharma operates within the biotechnology and healthcare sectors, aiming to leverage cutting-edge research to provide innovative therapeutic solutions.